We're excited to report the full Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor — including a newly announced 60 mg once-daily cohort that matched the profound hsCRP reductions of our previously reported 120 mg dose in participants with obesity and elevated inflammation. Combined with oral convenience and tissue penetration that extends beyond the periphery, we believe BGE-102 has the potential to be a "pipeline in a pill" — a single therapy addressing NLRP3-driven inflammation across cardiovascular, ocular, and CNS disease — and to do for cardiovascular inflammation what statins did for cholesterol. Read the release: globenewswire.com/news-relea… Headline results: • In participants with obesity and elevated hsCRP: 86% median hsCRP reduction at both once-daily doses • ≥87% of active-treatment participants reached hsCRP <2 mg/L, the clinical threshold for reduced cardiovascular risk • Consistent reductions in additional markers of CVD risk • Well tolerated at every dose level What's next: • Phase 2 dose-ranging POC trial in cardiovascular risk, with hsCRP as the primary endpoint; data expected 2H26 • Phase 1b/2a proof-of-concept trial in diabetic macular edema; data expected mid-2027 • CMC, regulatory, and clinical activities underway to enable Phase 3 initiation in 2027 Aging biology in action: Chronic, low-grade inflammation — "inflammaging" — is a core hallmark of biological aging and a clinically validated driver of CVD. NLRP3 sits upstream of several inflammatory mediators (IL-1β, IL-6, hsCRP, fibrinogen) that independently predict cardiovascular risk, and prior trials of other anti-inflammatory therapies showed that reducing hsCRP below 2 mg/L was associated with a 25% reduction in major adverse cardiovascular events. BGE-102 emerged from BioAge's discovery platform, which draws on decades of longitudinal human aging data and surfaced NLRP3 as a target from the observation that reduced NLRP3 activity tracks with greater longevity. Join our conference call and webcast this morning at 8 AM ET for a full walkthrough of the data — link in release.

New Editor's Choice 🏅 article from #ACSChemBiol! Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach Read for free 👉 go.acs.org/3rB